<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03625323</url>
  </required_header>
  <id_info>
    <org_study_id>TACTI-002</org_study_id>
    <secondary_id>Keynote-PN798</secondary_id>
    <nct_id>NCT03625323</nct_id>
  </id_info>
  <brief_title>Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC</brief_title>
  <acronym>TACTI-002</acronym>
  <official_title>TACTI-002 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Phase II Study in Patients With Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC), or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic Squamous Head and Neck Cancer (HNSCC) Receiving the Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) in Combination With Pembrolizumab (PD-1 Antagonist)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immutep S.A.S.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Immutep S.A.S.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab&#xD;
      in non-small cell lung carcinoma and head and neck carcinoma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 183 patients will be recruited in the TACTI-002 (Two ACTive Immunotherapies) Phase II&#xD;
      study which will take place across approximately 15 study centres in the U.S., Europe and&#xD;
      Australia. It will evaluate the safety and efficacy of the combination of eftilagimod alpha&#xD;
      with pembrolizumab in patients with advanced or metastatic non-small cell lung carcinoma or&#xD;
      head and neck carcinoma. It will be a Simon's two-stage, non-comparative, open-label,&#xD;
      single-arm, multicentre clinical study. Patients participating in the trial will be given the&#xD;
      combination treatment for 12 months using a 30 mg s.c. eftilagimod alpha dosing every 2 or 3&#xD;
      weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2019</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of objective response rate (ORR) according to iRECIST</measure>
    <time_frame>up to 24 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of (serious) adverse events</measure>
    <time_frame>up to 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of (serious) adverse events</measure>
    <time_frame>up to 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of (serious) adverse events</measure>
    <time_frame>up to 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to responses according to iRECIST and RECIST 1.1</measure>
    <time_frame>up to 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of responses according to iRECIST and RECIST 1.1</measure>
    <time_frame>up to 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate according to RECIST 1.1</measure>
    <time_frame>up to 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate according to iRECIST and RECIST 1.1</measure>
    <time_frame>up to 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 42 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 42 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of eftilagimod alpha-specific antibodies (ADA)</measure>
    <time_frame>up to 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration time profile of eftilagimod alpha</measure>
    <time_frame>up to 24 month</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">183</enrollment>
  <condition>NSCLC</condition>
  <condition>HNSCC</condition>
  <arm_group>
    <arm_group_label>1st line NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).&#xD;
Pembrolizumab: 200 mg every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2nd line NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).&#xD;
Pembrolizumab: 200 mg every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HNSCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).&#xD;
Pembrolizumab: 200 mg every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eftilagimod alpha</intervention_name>
    <description>APC activator, MHC II agonist, LAG-3 fusion protein</description>
    <arm_group_label>1st line NSCLC</arm_group_label>
    <arm_group_label>2nd line NSCLC</arm_group_label>
    <arm_group_label>HNSCC</arm_group_label>
    <other_name>IMP321</other_name>
    <other_name>Efti</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>anti-PD-1 antibody</description>
    <arm_group_label>1st line NSCLC</arm_group_label>
    <arm_group_label>2nd line NSCLC</arm_group_label>
    <arm_group_label>HNSCC</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Part A (1st line, PD-X naïve NSCLC): histologically- or cytologically-confirmed&#xD;
             diagnosis of non-small cell lung carcinoma stage IIIB not amenable to curative&#xD;
             treatment or stage IV not amenable to EGFR/ALK based therapy, treatment naïve for&#xD;
             systemic therapy given for advanced/metastatic disease (previous palliative&#xD;
             radiotherapy for advanced/metastatic disease acceptable)&#xD;
&#xD;
             Part B (2nd line, PD-X refractory NSCLC): histologically- or cytologically-confirmed&#xD;
             diagnosis of NSCLC after failure of first-line treatment (for metastatic disease) with&#xD;
             at least 2 cycles of any PD-1/PD-L1 containing based therapy (e.g. nivolumab,&#xD;
             pembrolizumab, avelumab, durvalumab, etc.) alone, or in combination with any other&#xD;
             immunotherapeutic or chemotherapy given as part of first-line treatment.&#xD;
&#xD;
             Part C (2nd line PD-X naive HNSCC): Histologically- or cytologically-confirmed&#xD;
             recurrent disease not amenable to curative treatment with local or systemic therapy,&#xD;
             or metastatic (disseminated) HNSCC of the oral cavity, oropharynx, hypopharynx, and&#xD;
             larynx that is considered incurable by local therapies after failure of prior&#xD;
             platinum-based therapy.&#xD;
&#xD;
          2. Submission of formalin-fixed diagnostic tumor tissue&#xD;
&#xD;
          3. ECOG performance status 0-1.&#xD;
&#xD;
          4. Expected survival &gt; 3 months.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. For part A (1st line, PD-X naïve NSCLC):&#xD;
&#xD;
               -  The NSCLC can be treated with curative intent with either surgical resection&#xD;
                  and/or chemoradiation and/or radiation.&#xD;
&#xD;
               -  Has received systemic therapy for the treatment of their stage IV NSCLC.&#xD;
                  Completion of treatment with chemotherapy and/or radiation as part of&#xD;
                  neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least&#xD;
                  6 months prior to the diagnosis of metastatic disease.&#xD;
&#xD;
               -  EGFR-sensitizing mutation and/or is EML4 gene/ ALK gene fusion positive (ALK&#xD;
                  translocation).&#xD;
&#xD;
               -  Lung radiation therapy that is &gt;30Gy within 6 months of the first dose of trial&#xD;
                  treatment.&#xD;
&#xD;
             For Part B (2nd line, PD-X refractory NSCLC):&#xD;
&#xD;
               -  Symptomatic ascites or pleural effusion.&#xD;
&#xD;
               -  &gt; 1 line of chemotherapy for metastatic disease.&#xD;
&#xD;
               -  Lung radiation therapy that is &gt;30Gy within 6 months of the first dose of trial&#xD;
                  treatment.&#xD;
&#xD;
             For Part C (2nd line PD-X naive HNSCC):&#xD;
&#xD;
               -  Disease is suitable for local therapy administered with curative intent.&#xD;
&#xD;
               -  Previously treated with &gt; 1 systemic regimens for recurrent and/or metastatic&#xD;
                  disease.&#xD;
&#xD;
          2. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic&#xD;
             T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other&#xD;
             antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)&#xD;
             (Part A and C only)&#xD;
&#xD;
          3. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with&#xD;
             an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,&#xD;
             CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or&#xD;
             higher irAE (Part B only)&#xD;
&#xD;
          4. Has received prior chemotherapy, anti-cancer monoclonal antibody, major surgery,&#xD;
             another systemic cancer therapy or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks prior to cycle 1 day 1.&#xD;
&#xD;
             Note: Patients must have recovered from all AEs due to previous therapies to ≤Grade 1&#xD;
             or baseline. Patients with ≤Grade 2 neuropathy, alopecia and elevated transaminases in&#xD;
             case of liver metastases may be eligible. If patient received major surgery, they must&#xD;
             have recovered adequately from the toxicity and/or complications from the intervention&#xD;
             prior to starting study treatment. Participants who have entered the follow-up phase&#xD;
             of an investigational study may participate as long as it has been 4 weeks after the&#xD;
             last dose of the previous investigational agent.&#xD;
&#xD;
          5. Known active central nervous system metastasis and/or carcinomatous meningitis.&#xD;
             Patients with previously treated brain metastases may participate provided they are&#xD;
             radiologically stable: i.e. without evidence of progression documented by repeat&#xD;
             imaging performed after therapy completed for CNS metastasis and with at least 4 weeks&#xD;
             difference, clinically stable and without requirement for steroid treatment for at&#xD;
             least 14 days prior to cycle 1 day 1.&#xD;
&#xD;
          6. Receives continuous systemic treatment with either corticosteroids (&gt;10 mg daily&#xD;
             prednisone equivalents) or other immunosuppressive medications within 7 days prior to&#xD;
             cycle 1 day 1. Inhaled or topical steroids and physiological replacement doses of up&#xD;
             to 10 mg daily prednisone equivalents are permitted in the absence of active&#xD;
             auto-immune disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Frederic Triebel</last_name>
    <phone>+33660916539</phone>
    <email>frederic.triebel@immutep.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wade T. Iams, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Peguero, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tasman Health Care</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pawan Bajaj, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St John of God Subiaco Hospital</name>
      <address>
        <city>Perth</city>
        <zip>WA 6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Clay, Dr.</last_name>
      <phone>+61864659204</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Med Polonia Sp. z o.o.</name>
      <address>
        <city>Poznań</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodryg Ramlau, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut MSF Sp. z o.o.</name>
      <address>
        <city>Łódź</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Kalinka, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarita Majem, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall d' Hebron Institute of Oncology (VHIO) Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enriqueta Felip, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Consorci Corporació Sanitària Parc Taulí de Sabadell</name>
      <address>
        <city>Barcelona</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laia Vilà Martínez, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia Badalona-Hospital Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enric Carcereny, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Begoña Campos Balea, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Doger, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gema María García Ledo, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Cobo Dols, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise &quot;City Clinical Hospital #4&quot; of Dnipro City Council</name>
      <address>
        <city>Dnipro</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Bondarenko, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kharkov Medical Academy of Postgraduate Education</name>
      <address>
        <city>Kharkiv</city>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleksandr Dudnichenko, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical and Diagnostic Centre of Private Enterprise of Private Manufacturing Company &quot;Acinus&quot;</name>
      <address>
        <city>Kropyvnytskyi</city>
        <zip>25006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grygorii Ursol, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Roxburgh, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation</name>
      <address>
        <city>London</city>
        <zip>W1T 7HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Forster, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Krebs, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

